Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes.: Epibatidine analogues

被引:77
作者
Carroll, FI
Liang, F
Navarro, HA
Brieaddy, LE
Abraham, P
Damaj, MI
Martin, BR
机构
[1] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
关键词
D O I
10.1021/jm0100178
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A convenient, high-yield synthesis of 7-tert-butoxycarbonyl-7-azabicyclo[2.2.1]hept-2-ene (5), which involved the addition of tributyltin hydride to 7-tert-butoxycarbonyl-2-p-toluenesulfonyl-7-azabicyclo[2.2.1]hept-2-ene (4) followed by elimination of the tributyltin and p-tolylsulfonyl groups using tetrabutylammonium fluoride was developed. The addition of 2-amino-5-iodopyridine to 5 under reductive. Heck conditions provided 7-tert-butoxycarbonyl-2-exo-(2 ' -amino-5 ' -pyridinyl)-7-azabicyclo [2.2.1]heptane (6). Compound 6 was the key intermediate used to prepare epibatidine analogues where the 2 ' -chloro group on the pyridine ring was replaced with a fluorine (Ib), bromine (1c), iodine (1d), hydroxy (1e), amino (1f), dimethylamino (1g), trifluoromethanesulfonate (1h), and hydrogen (1i) group. (+)- and (-)-Epibatidine and compounds 1b-d and Ii all possess similar binding affinities at the alpha (4)beta (2) nAChR receptors labeled by [H-3]epibatidine. Compound If has affinity similar to nicotine, whereas compounds le, Ig, and Ih have much lower affinity. The binding affinity appears to be dependent upon the electronic nature of the substituent. However, other factors are also involved. None of the compounds possesses appreciable affinity for the alpha (7) nAChR labeled by [I-125]iodo-MLA. With the exception of If and Ig, all the epibatidine analogues are full agonists (tail flick test) in producing antinociception after intrathecal injection in mice.
引用
收藏
页码:2229 / 2237
页数:9
相关论文
共 29 条
  • [1] TOTAL SYNTHESIS OF (+/-)-EPIBATIDINE
    ALBERTINI, E
    BARCO, A
    BENETTI, S
    DERISI, C
    POLLINI, GP
    ROMAGNOLI, R
    ZANIRATO, V
    [J]. TETRAHEDRON LETTERS, 1994, 35 (49) : 9297 - 9300
  • [2] [Anonymous], NEURONAL NICOTINIC R
  • [3] BADIO B, 1994, MOL PHARMACOL, V45, P563
  • [4] New synthesis of 7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hept-2-ene.: A key intermediate in the synthesis of epibatidine and analogs
    Brieaddy, LE
    Liang, F
    Abraham, P
    Lee, JR
    Carroll, FI
    [J]. TETRAHEDRON LETTERS, 1998, 39 (30) : 5321 - 5322
  • [5] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [6] A TOTAL SYNTHESIS OF (PLUS-OR-MINUS)-EPIBATIDINE
    CLAYTON, SC
    REGAN, AC
    [J]. TETRAHEDRON LETTERS, 1993, 34 (46) : 7493 - 7496
  • [7] D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
  • [8] SYNTHESIS AND SIGMA-BINDING-PROPERTIES OF 2'-SUBSTITUTED 5,9-ALPHA-DIMETHYL-6,7-BENZOMORPHANS
    DANSODANQUAH, R
    BAI, X
    ZHANG, X
    MASCARELLA, SW
    WILLIAMS, W
    SINE, B
    BOWEN, WD
    CARROLL, FI
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (15) : 2978 - 2985
  • [9] DavilaGarcia MI, 1997, J PHARMACOL EXP THER, V282, P445
  • [10] Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP:: Kinetics, nicotine effect, and toxicity
    Ding, YS
    Molina, PE
    Fowler, JS
    Logan, J
    Volkow, ND
    Kuhar, MJ
    Carroll, FI
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (01) : 139 - 148